Peijia Medical-B (09996.HK) Rises Nearly 3% on Strong H1 Revenue Growth of 28.9%–37.8% and Acquisition of Licensing Partner JenaValve by Edwards Lifesciences

According to the Zhisheng Finance APP, Peijia Medical-B (09996) rose nearly 3%. As of the time of writing, it increased by 2.66%, trading at HK$2.70, with a turnover of HK$1.1849 million.

On the news front, Peijia Medical-B announced that the group achieved revenue of approximately RMB 290 million to RMB 310 million for the six months ended June 30, 2024, representing a year-on-year increase of approximately 28.9% to 37.8%.

Notably, Peijia Medical-B issued an announcement stating that on July 24, 2024, JenaValve Technology, Inc. (JenaValve) notified the company that Edwards Lifesciences Corporation had agreed to acquire JenaValve through a merger. Edwards Lifesciences Corporation is a company listed on the New York Stock Exchange and a global leader in patient-focused innovations for structural heart disease and critical care monitoring.